Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn’s Disease Are Associated With Biologic Remission

Adalimumab is an established treatment for Crohn’s disease. Limited data are available regarding the relationship between adalimumab drug levels and serum/fecal markers of gut inflammation. We therefore aimed to characterize the relationship between adalimumab levels and biologic remission during maintenance therapy. A single-center prospective cross-sectional study was undertaken on Crohn’s disease patients who had received adalimumab therapy...